BamSEC and AlphaSense Join Forces
Learn More

BioMarin Pharmaceutical Inc.

NASDAQ: BMRN    
Share price (12/23/24): $66.27    
Market cap (12/23/24): $12.6 billion
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.6
from 10-K 5 pages First Amendment to the Amended and Restated Termination and Transition Agreement
12/34/56
EX-2.5
from 10-K 63 pages Termination and Transition Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. 1
12/34/56
EX-2.4
from 10-K 30 pages Termination Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. 1
12/34/56
EX-2.3
from 10-K 57 pages Amended and Restated Termination and Transition Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. 1
12/34/56
EX-2.3
from 8-K 56 pages Termination and Transition Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. - 1
12/34/56
EX-2.2
from 8-K 30 pages Termination Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. - 1
12/34/56
EX-2.1
from 8-K 55 pages Amended and Restated Termination and Transition Agreement by and Between Biomarin Pharmaceutical Inc., a Delaware Corporation, and Ares Trading S.A. - 1
12/34/56
EX-2.1
from 8-K 44 pages Asset Purchase Agreement by and Between Biomarin Pharmaceutical Inc. and Medivation, Inc. August 21, 2015 Asset Purchase Agreement Article 1. Definitions
12/34/56
EX-2
from SC TO-C 84 pages Purchase Agreement Dated as of November 23, 2014 Among Prosensa Holding N.V., Biomarin Pharmaceutical Inc. and Biomarin Falcons B.V
12/34/56
EX-2
from 8-K 84 pages Purchase Agreement Dated as of November 23, 2014 Among Prosensa Holding N.V., Biomarin Pharmaceutical Inc. and Biomarin Falcons B.V
12/34/56
EX-2.1
from 8-K 101 pages Redacted Portions Are Indicated by [****]. Redacted Portions Filed Separately With Confidential Treatment Application. Securities Purchase Agreement by and Among: Biomarin Pharmaceutical Inc., a Delaware Corporation; Zystor Therapeutics, Inc., a Delaware Corporation; the Persons Listed on Exhibit 1.4a and George G. Arida, as the Selling Holder Representative Dated as of August 17, 2010
12/34/56
EX-2.6
from 10-K 4 pages Amendment to License Agreement
12/34/56
EX-2.5
from 10-K 4 pages Amendment to Securities Purchase Agreement
12/34/56
EX-2.4
from 10-K 8 pages Settlement Agreement and Mutual Release
12/34/56
EX-2.1
from SC 13G 1 page Statement of Control Person
12/34/56
EX-2.1
from SC 13G 1 page Statement of Control Person
12/34/56
EX-2.1
from SC 13G 1 page Statement of Control Person
12/34/56
EX-2.1
from SC 13G 1 page Statement of Control Person
12/34/56
EX-2.3
from 8-K 46 pages License Agreement
12/34/56
EX-2.2
from 8-K 57 pages Securities Purchase Agreement Among Medicis Pharmaceutical Corporation, a Delaware Corporation, Ascent Pediatrics, Inc., a Delaware Corporation, Biomarin Pharmaceutical Inc., a Delaware Corporation and Biomarin Pediatrics Inc., a Delaware Corporation Dated as of May 18, 2004
12/34/56